

Patent number:	FR2694196
Publication date:	1994-02-04
Inventor:	SERGE ROLLAN; CHRISTIAN DESHAYES
Applicant:	ROCHADE (FR)
Classification:	
- international:	A61K37/64; A61K31/505; A61K31/19; A61K31/70; A61K31/17
- european:	A61K38/55
Application number:	FR19920009601 19920730
Priority number(s):	FR19920009601 19920730

Compsns. active against tumour viruses - obtained by double fermentation of milk or whey using specified starter

Abstract of FR2694196

Medicinal compsns. contain protease-inhibiting peptides (I) with a molecular wt. below 30kD, one or more orotic acid salts (II), and L(+)-lactic acid (III). Pref. the compsns. are obtained by double fermentation of milk or whey with a starter comprising polysaccharides in soln., *Candida pseudotropicalis*, *Pichia membranaefaciens*, *Lactococcus* spp., *Lactobacillus* spp. and opt. *Bifidobacterium*, *Acetobacter* and *Leuconostoc* spp.

USE - The compsns. have antiviral activity, esp. against oncogenic viruses, e.g. mammary tumour virus (MTV) in mice and Peyton sarcoma and erythromyeloblastic leukaemia viruses in chickens. In an example, the starter was prepd. by fermenting semi-skimmed milk 'RDR91A) at 30 deg.C for 20 hours and freeze drying the liq. phase. A mixt. of milk and skim-milk powder (12.5% solids) was inoculated with the starter, fermented at 30 deg.C for 6 hours and at 21 deg.C for 12 hours, pasteurised at 95 deg.C for 5 minutes, concd. by vacuum evapn. at 25 deg.C, and freeze dried. C3H/Bi mice (neonatally infected with MTV) receiving drinking water contg. 5% of the prod. showed a tumour incidence of 30% (90% for controls) and had a mean survival time of 84 days (37 days for controls).